

References

- Abdi, J., Rastgoo, N., Li, L., Chen, W., & Chang, H. (2017). Role of tumor suppressor p53 and micro-RNA interplay in multiple myeloma pathogenesis. *Journal of Hematology & Oncology*, *10*(1), 169. <https://doi.org/10.1186/s13045-017-0538-4>
- Atallah-Yunes, S. A., & Soe, M. H. (2018). Drug-Induced Thrombotic Microangiopathy due to Cumulative Toxicity of Ixazomib. *Case Reports in Hematology*, *2018*, 7063145. <https://doi.org/10.1155/2018/7063145>
- Barwick, B. G., Gupta, V. A., Vertino, P. M., & Boise, L. H. (2019). Cell of Origin and Genetic Alterations in the Pathogenesis of Multiple Myeloma. *Frontiers in Immunology*, *10*, 1121. <https://doi.org/10.3389/fimmu.2019.01121>
- Bhattacharya, S., Chakraborty, D., Basu, M., & Ghosh, M. K. (2018). Emerging insights into HAUSP (USP7) in physiology, cancer and other diseases. *Signal Transduction and Targeted Therapy*, *3*(1), 17. <https://doi.org/10.1038/s41392-018-0012-y>
- Bhattacharya, S., & Ghosh, M. K. (2014). HAUSP, a novel deubiquitinase for Rb - MDM2 the critical regulator. *The FEBS Journal*, *281*(13), 3061–3078. <https://doi.org/10.1111/febs.12843>
- Blau, O., Berenstein, R., Wächter, M., Nogai, A., Künel, A., Bayanova, M., & Blau, I. W. (2019). Molecular Aberrations in Bone Marrow Stromal Cells in Multiple Myeloma. In M. T. Valarmathi (Ed.), *Stromal Cells*. IntechOpen. <https://doi.org/10.5772/intechopen.77179>
- Bosshard, M., Aprigliano, R., Gattiker, C., Palibrk, V., Markkanen, E., Backe, P. H., Pellegrino, S., Raymond, F. L., Froyen, G., Altmeyer, M., Bjørås, M., Dianov, G. L., & van Loon, B. (2017). Impaired oxidative stress response characterizes HUWE1-promoted X-linked intellectual disability. *Scientific Reports*, *7*(1), 15050. <https://doi.org/10.1038/s41598-017-15380-y>
- Boutell, C., Canning, M., Orr, A., & Everett, R. D. (2005). Reciprocal Activities between Herpes Simplex Virus Type 1 Regulatory Protein ICP0, a Ubiquitin E3 Ligase, and Ubiquitin-Specific Protease USP7. *Journal of Virology*, *79*(19), 12342 LP – 12354. <https://doi.org/10.1128/JVI.79.19.12342-12354.2005>
- Chauhan, D., Tian, Z., Nicholson, B., Kumar, K. G. S., Zhou, B., Carrasco, R., McDermott, J. L., Leach, C. A., Fulciniti, M., Kodrasov, M. P., Weinstock, J., Kingsbury, W. D., Hideshima, T., Shah, P. K., Minvielle, S., Altun, M., Kessler, B. M., Orlowski, R., Richardson, P., ... Anderson, K. C. (2012). A small molecule inhibitor of ubiquitin-specific protease-7 induces apoptosis in multiple myeloma cells and overcomes bortezomib resistance. *Cancer Cell*, *22*(3), 345–358. <https://doi.org/10.1016/j.ccr.2012.08.007>
- Cho, H. I., Kim, M. S., Lee, J., Yoo, B. C., Kim, K. H., Choe, K.-M., & Jang, Y. K. (2020). BRPF3-HUWE1-mediated regulation of MYST2 is required for differentiation and cell-cycle progression in embryonic stem cells. *Cell Death & Differentiation*. <https://doi.org/10.1038/s41418-020-0577-1>
- Colleran, A., Collins, P. E., O'Carroll, C., Ahmed, A., Mao, X., McManus, B., Kiely, P. A., Burstein, E., & Carmody, R. J. (2013). Deubiquitination of NF-κB by Ubiquitin-Specific Protease-7 promotes transcription. *Proceedings of the National Academy of Sciences*, *110*(2), 618–623. <https://doi.org/10.1073/PNAS.1208446110>
- Crawford, L. J., Campbell, D. C., Morgan, J. J., Lawson, M. A., Down, J. M., Chauhan, D., McAvera, R. M., Morris, T. C., Hamilton, C., Krishnan, A., Rajalingam, K., Chantry, A. D., & Irvine, A. E. (2020). The E3 ligase HUWE1 inhibition as a therapeutic strategy to target MYC in multiple myeloma. *Oncogene*, *39*(27), 5001–5014. <https://doi.org/10.1038/s41388-020-1345-x>

- Crawford, L. J., & Irvine, A. E. (2013). Targeting the ubiquitin proteasome system in haematological malignancies. *Blood Reviews*, 27(6), 297–304. <https://doi.org/10.1016/j.blre.2013.10.002>
- Crawford, L. J., & Irvine, A. E. (2018). *Ubiquitination and DNA Repair in Multiple Myeloma* (A. E. I. E.-E. B. E.-H.-W. Stürzbecher (ed.); p. Ch. 9). IntechOpen. <https://doi.org/10.5772/intechopen.70800>
- Edfors, F., Danielsson, F., Hallström, B. M., Käll, L., Lundberg, E., Pontén, F., Forsström, B., & Uhlén, M. (2016). Gene-specific correlation of RNA and protein levels in human cells and tissues. *Molecular Systems Biology*, 12(10), 883. <https://doi.org/10.15252/msb.20167144>
- Gandolfi, S., Laubach, J. P., Hideshima, T., Chauhan, D., Anderson, K. C., & Richardson, P. G. (2017). The proteasome and proteasome inhibitors in multiple myeloma. *Cancer Metastasis Reviews*, 36(4), 561–584. <https://doi.org/10.1007/s10555-017-9707-8>
- Garcia-Gomez, A., Sanchez-Guijo, F., Del Cañizo, M. C., San Miguel, J. F., & Garayoa, M. (2014). Multiple myeloma mesenchymal stromal cells: Contribution to myeloma bone disease and therapeutics. *World Journal of Stem Cells*, 6(3), 322–343. <https://doi.org/10.4252/wjsc.v6.i3.322>
- Gavory, G., O’Dowd, C. R., Helm, M. D., Flasz, J., Arkoudis, E., Dossang, A., Hughes, C., Cassidy, E., McClelland, K., Odrzywol, E., Page, N., Barker, O., Miel, H., & Harrison, T. (2018). Discovery and characterization of highly potent and selective allosteric USP7 inhibitors. *Nature Chemical Biology*, 14(2), 118–125. <https://doi.org/10.1038/nchembio.2528>
- González, D., van der Burg, M., García-Sanz, R., Fenton, J. A., Langerak, A. W., González, M., van Dongen, J. J. M., San Miguel, J. F., & Morgan, G. J. (2007). Immunoglobulin gene rearrangements and the pathogenesis of multiple myeloma. *Blood*, 110(9), 3112–3121. <https://doi.org/10.1182/blood-2007-02-069625>
- Greenbaum, D., Colangelo, C., Williams, K., & Gerstein, M. (2003). Comparing protein abundance and mRNA expression levels on a genomic scale. *Genome Biology*, 4(9), 117. <https://doi.org/10.1186/gb-2003-4-9-117>
- Greenstein, S., Krett, N. L., Kurosawa, Y., Ma, C., Chauhan, D., Hideshima, T., Anderson, K. C., & Rosen, S. T. (2003). Characterization of the MM.1 human multiple myeloma (MM) cell lines: A model system to elucidate the characteristics, behavior, and signaling of steroid-sensitive and -resistant MM cells. In *Experimental Hematology*. [https://doi.org/10.1016/S0301-472X\(03\)00023-7](https://doi.org/10.1016/S0301-472X(03)00023-7)
- Gupta, V. A., Matulis, S. M., Conage-Pough, J. E., Nooka, A. K., Kaufman, J. L., Lonial, S., & Boise, L. H. (2017). Bone marrow microenvironment-derived signals induce Mcl-1 dependence in multiple myeloma. *Blood*, 129(14), 1969–1979. <https://doi.org/10.1182/blood-2016-10-745059>
- Hao, Z., Duncan, G. S., Su, Y.-W., Li, W. Y., Silvester, J., Hong, C., You, H., Brenner, D., Gorrini, C., Haight, J., Wakeham, A., You-Ten, A., McCracken, S., Elia, A., Li, Q., Detmar, J., Jurisicova, A., Hobeika, E., Reth, M., ... Mak, T. W. (2012). The E3 ubiquitin ligase Mule acts through the ATM-p53 axis to maintain B lymphocyte homeostasis. *The Journal of Experimental Medicine*, 209(1), 173–186. <https://doi.org/10.1084/jem.20111363>
- He, Y., Wang, S., Tong, J., Jiang, S., Yang, Y., Zhang, Z., Xu, Y., Zeng, Y., Cao, B., Moran, M. F., & Mao, X. (2020). The deubiquitinase USP7 stabilizes Maf proteins to promote myeloma cell survival. *Journal of Biological Chemistry*, 295(7), 2084–2096. <https://doi.org/10.1074/jbc.RA119.010724>
- Hetz, C. (2012). The unfolded protein response: controlling cell fate decisions under ER stress and beyond. *Nature Reviews Molecular Cell Biology*, 13(2), 89–102.

<https://doi.org/10.1038/nrm3270>

- Hideshima, T., Richardson, P. G., & Anderson, K. C. (2011). Mechanism of Action of Proteasome Inhibitors and Deacetylase Inhibitors and the Biological Basis of Synergy in Multiple Myeloma. *Molecular Cancer Therapeutics*, *10*(11), 2034 LP – 2042. <https://doi.org/10.1158/1535-7163.MCT-11-0433>
- Hu, Y., Chen, W., Chen, S., & Huang, Z. (2016). Cytogenetic abnormality in patients with multiple myeloma analyzed by fluorescent in situ hybridization. *OncoTargets and Therapy*, *9*, 1145–1149. <https://doi.org/10.2147/OTT.S95818>
- Huang, F.-I., Wu, Y.-W., Sung, T.-Y., Liou, J.-P., Lin, M.-H., Pan, S.-L., & Yang, C.-R. (2019). MPTOG413, A Novel HDAC6-Selective Inhibitor, and Bortezomib Synergistically Exert Anti-tumor Activity in Multiple Myeloma Cells. *Frontiers in Oncology*, *9*, 249. <https://doi.org/10.3389/fonc.2019.00249>
- Hughes, P., Marshall, D., Reid, Y., Parkes, H., & Gelber, C. (2007). The costs of using unauthenticated, over-passaged cell lines: how much more data do we need? *BioTechniques*, *43*(5), 575–586. <https://doi.org/10.2144/000112598>
- Inoue, S., Hao, Z., Elia, A. J., Cescon, D., Zhou, L., Silvester, J., Snow, B., Harris, I. S., Sasaki, M., Li, W. Y., Isumi, M., Yamamoto, K., Ueda, T., Dominguez-Brauer, C., Gorrini, C., Chio, I. I. C., Haight, J., You-Ten, A., McCracken, S., ... Mak, T. W. (2013). Mule/Huwe1/Arf-BP1 suppresses Ras-driven tumorigenesis by preventing c-Myc/Miz1-mediated down-regulation of p21 and p15. *Genes & Development*, *27*(10), 1101–1114. <https://doi.org/10.1101/gad.214577.113>
- Janz, S., Zhan, F., Sun, F., Cheng, Y., Pisano, M., Yang, Y., Goldschmidt, H., & Hari, P. (2019). Germline Risk Contribution to Genomic Instability in Multiple Myeloma. *Frontiers in Genetics*, *10*, 424. <https://doi.org/10.3389/fgene.2019.00424>
- Jovanović, K. K., Roche-Lestienne, C., Ghobrial, I. M., Facon, T., Quesnel, B., & Manier, S. (2018). Targeting MYC in multiple myeloma. *Leukemia*, *32*(6), 1295–1306. <https://doi.org/10.1038/s41375-018-0036-x>
- Kao, S.-H., Wu, H.-T., & Wu, K.-J. (2018). Ubiquitination by HUWE1 in tumorigenesis and beyond. *Journal of Biomedical Science*, *25*(1), 67. <https://doi.org/10.1186/s12929-018-0470-0>
- Kategaya, L., Di Lello, P., Rougé, L., Pastor, R., Clark, K. R., Drummond, J., Kleinheinz, T., Lin, E., Upton, J.-P., Prakash, S., Heideker, J., McClelland, M., Ritorto, M. S., Alessi, D. R., Trost, M., Bainbridge, T. W., Kwok, M. C. M., Ma, T. P., Stiffler, Z., ... Wertz, I. E. (2017). USP7 small-molecule inhibitors interfere with ubiquitin binding. *Nature*, *550*(7677), 534–538. <https://doi.org/10.1038/nature24006>
- Kazandjian, D. (2016). Multiple myeloma epidemiology and survival: A unique malignancy. *Seminars in Oncology*, *43*(6), 676–681. <https://doi.org/10.1053/j.seminoncol.2016.11.004>
- Khoronenkova, S. V., & Dianov, G. L. (2013). USP7S-dependent inactivation of Mule regulates DNA damage signalling and repair. *Nucleic Acids Research*, *41*(3), 1750–1756. <https://doi.org/10.1093/nar/gks1359>
- Kon, N., Kobayashi, Y., Li, M., Brooks, C. L., Ludwig, T., & Gu, W. (2010). Inactivation of HAUSP in vivo modulates p53 function. *Oncogene*, *29*(9), 1270–1279. <https://doi.org/10.1038/onc.2009.427>
- Kumar, S. K., Rajkumar, V., Kyle, R. A., van Duin, M., Sonneveld, P., Mateos, M.-V., Gay, F., & Anderson, K. C. (2017). Multiple myeloma. *Nature Reviews Disease Primers*, *3*(1), 17046. <https://doi.org/10.1038/nrdp.2017.46>

- Kumar, S., Moreau, P., Hari, P., Mateos, M.-V., Ludwig, H., Shustik, C., Masszi, T., Spencer, A., Hájek, R., Romeril, K., Avivi, I., Liberati, A. M., Minnema, M. C., Einsele, H., Lonial, S., Berg, D., Lin, J., Gupta, N., Esseltine, D.-L., & Richardson, P. G. (2017). Management of adverse events associated with ixazomib plus lenalidomide/dexamethasone in relapsed/refractory multiple myeloma. *British Journal of Haematology*, *178*(4), 571–582. <https://doi.org/10.1111/bjh.14733>
- Landgren, O., Kyle, R. A., Pfeiffer, R. M., Katzmann, J. A., Caporaso, N. E., Hayes, R. B., Dispenzieri, A., Kumar, S., Clark, R. J., Baris, D., Hoover, R., & Rajkumar, S. V. (2009). Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study. *Blood*, *113*(22), 5412–5417. <https://doi.org/10.1182/blood-2008-12-194241>
- Leger, P. R., Hu, D. X., Biannic, B., Bui, M., Han, X., Karbarz, E., Maung, J., Okano, A., Osipov, M., Shibuya, G. M., Young, K., Higgs, C., Abraham, B., Bradford, D., Cho, C., Colas, C., Jacobson, S., Ohol, Y. M., Pookot, D., ... Wustrow, D. J. (2020). Discovery of Potent, Selective, and Orally Bioavailable Inhibitors of USP7 with In Vivo Antitumor Activity. *Journal of Medicinal Chemistry*, *63*(10), 5398–5420. <https://doi.org/10.1021/acs.jmedchem.0c00245>
- Lin, Y.-C., Shun, C.-T., Wu, M.-S., & Chen, C.-C. (2006). A Novel Anticancer Effect of Thalidomide: Inhibition of Intercellular Adhesion Molecule-1–Mediated Cell Invasion and Metastasis through Suppression of Nuclear Factor- κ B. *Clinical Cancer Research*, *12*(23), 7165 LP – 7173. <https://doi.org/10.1158/1078-0432.CCR-06-1393>
- Lubbers, E. R., & Mohler, P. J. (2016). Roles and regulation of protein phosphatase 2A (PP2A) in the heart. *Journal of Molecular and Cellular Cardiology*, *101*, 127–133. <https://doi.org/10.1016/j.yjmcc.2016.11.003>
- Manasanch, E. E., & Orlowski, R. Z. (2017). Proteasome inhibitors in cancer therapy. *Nature Reviews Clinical Oncology*, *14*(7), 417–433. <https://doi.org/10.1038/nrclinonc.2016.206>
- Markovina, S., Callander, N. S., O'Connor, S. L., Xu, G., Shi, Y., Leith, C. P., Kim, K., Trivedi, P., Kim, J., Hematti, P., & Miyamoto, S. (2010). Bone marrow stromal cells from multiple myeloma patients uniquely induce bortezomib resistant NF- κ B activity in myeloma cells. *Molecular Cancer*, *9*, 176. <https://doi.org/10.1186/1476-4598-9-176>
- McConathy, J., & Owens, M. J. (2003). Stereochemistry in Drug Action. *Primary Care Companion to the Journal of Clinical Psychiatry*, *5*(2), 70–73. <https://doi.org/10.4088/pcc.v05n0202>
- Moreaux, J., Klein, B., Bataille, R., Descamps, G., Maïga, S., Hose, D., Goldschmidt, H., Jauch, A., Rème, T., Jourdan, M., Amiot, M., & Pellat-Deceunynck, C. (2011). A high-risk signature for patients with multiple myeloma established from the molecular classification of human myeloma cell lines. *Haematologica*, *96*(4), 574–582. <https://doi.org/10.3324/haematol.2010.033456>
- Morgan, G. J., Walker, B. A., & Davies, F. E. (2012). The genetic architecture of multiple myeloma. *Nature Reviews Cancer*, *12*(5), 335–348. <https://doi.org/10.1038/nrc3257>
- Morgan, J. J., McAvera, R. M., & Crawford, L. J. (2019). TRAF6 Silencing Attenuates Multiple Myeloma Cell Adhesion to Bone Marrow Stromal Cells. *International Journal of Molecular Sciences*, *20*(3), 702. <https://doi.org/10.3390/ijms20030702>
- Myant, K. B., Cammareri, P., Hodder, M. C., Wills, J., Von Kriegsheim, A., Gyórfy, B., Rashid, M., Polo, S., Maspero, E., Vaughan, L., Gurung, B., Barry, E., Malliri, A., Camargo, F., Adams, D. J., Iavarone, A., Lasorella, A., & Sansom, O. J. (2017). HUWE1 is a critical colonic tumour suppressor gene that prevents MYC signalling, DNA damage accumulation and tumour initiation. *EMBO Molecular Medicine*, *9*(2), 181–197. <https://doi.org/10.15252/emmm.201606684>

- Nagaoka, H., Tran, T. H., Kobayashi, M., Aida, M., & Honjo, T. (2010). Preventing AID, a physiological mutator, from deleterious activation: regulation of the genomic instability that is associated with antibody diversity. *International Immunology*, *22*(4), 227–235. <https://doi.org/10.1093/intimm/dxq023>
- Nair, B., Waheed, S., Szymonifka, J., Shaughnessy Jr, J. D., Crowley, J., & Barlogie, B. (2009). Immunoglobulin isotypes in multiple myeloma: laboratory correlates and prognostic implications in total therapy protocols. *British Journal of Haematology*, *145*(1), 134–137. <https://doi.org/10.1111/j.1365-2141.2008.07547.x>
- Nikfarjam, L., & Farzaneh, P. (2012). Prevention and detection of Mycoplasma contamination in cell culture. *Cell Journal*, *13*(4), 203–212. <https://pubmed.ncbi.nlm.nih.gov/23508237>
- Otsuki, T., Nakazawa, N., Taniwaki, M., Yamada, O., Sakaguchi, H., Wada, H., Yawata, Y., & Ueki, A. (1998). Establishment of a new human myeloma cell line, KMS-18, having t(4;14)(p16.3;q32.3) derived from a case phenotypically transformed from Ig A-lambda to BJP-lambda, and associated with hyperammonemia. *International Journal of Oncology*, *12*(3), 545–552. <https://doi.org/10.3892/ijo.12.3.545>
- Oyajobi, B. O. (2007). Multiple myeloma/hypercalcemia. *Arthritis Research & Therapy*, *9* Suppl 1(Suppl 1), S4–S4. <https://doi.org/10.1186/ar2168>
- Padhi, S., Varghese, R. G., & Ramdas, A. (2013). Cyclin D1 expression in multiple myeloma by immunohistochemistry: Case series of 14 patients and literature review. *Indian Journal of Medical and Paediatric Oncology : Official Journal of Indian Society of Medical & Paediatric Oncology*, *34*(4), 283–291. <https://doi.org/10.4103/0971-5851.125246>
- Palumbo, A., & Anderson, K. (2011). Multiple Myeloma. *New England Journal of Medicine*, *364*(11), 1046–1060. <https://doi.org/10.1056/NEJMra1011442>
- Palumbo, A., Avet-Loiseau, H., Oliva, S., Lokhorst, H. M., Goldschmidt, H., Rosinol, L., Richardson, P., Caltagirone, S., Lahuerta, J. J., Facon, T., Bringhen, S., Gay, F., Attal, M., Passera, R., Spencer, A., Offidani, M., Kumar, S., Musto, P., Lonial, S., ... Moreau, P. (2015). Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group. *Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology*, *33*(26), 2863–2869. <https://doi.org/10.1200/JCO.2015.61.2267>
- Peter, S., Bultinck, J., Myant, K., Jaenicke, L. A., Walz, S., Müller, J., Gmachl, M., Treu, M., Boehmelt, G., Ade, C. P., Schmitz, W., Wiegering, A., Otto, C., Popov, N., Sansom, O., Kraut, N., & Eilers, M. (2014). Tumor cell-specific inhibition of MYC function using small molecule inhibitors of the HUWE1 ubiquitin ligase. *EMBO Molecular Medicine*, *6*(12), 1525–1541. <https://doi.org/10.15252/emmm.201403927>
- Pietrzak, M., & Puzianowska-Kuznicka, M. (2008). p53-dependent repression of the human MCL-1 gene encoding an anti-apoptotic member of the BCL-2 family: the role of Sp1 and of basic transcription factor binding sites in the MCL-1 promoter. *Biological Chemistry*, *389*(4), 383–393. <https://doi.org/10.1515/BC.2008.039>
- Qin, X.-Q., An, G., Li, Z.-J., Liu, L.-T., Xu, Y., Yang, L.-H., Ma, Y.-P., Deng, S.-H., Sui, W.-W., Qin, Y., Feng, X.-Y., Zang, M.-R., Yang, W.-J., Zhang, Y.-R., Yi, S.-H., Wang, T.-Y., Lv, R., Zou, D.-H., Zhao, Y.-Z., & Qiu, L.-G. (2019). Secretory status of monoclonal immunoglobulin is related to the outcome of patients with myeloma: a retrospective study. *Blood Advances*, *3*(5), 751–760. <https://doi.org/10.1182/bloodadvances.2018019851>
- Rajan, A. M., & Rajkumar, S. V. (2015). Interpretation of cytogenetic results in multiple myeloma for clinical practice. *Blood Cancer Journal*, *5*(10), e365–e365. <https://doi.org/10.1038/bcj.2015.92>

- Rajkumar, S. V. (2018). Multiple myeloma: 2018 update on diagnosis, risk-stratification, and management. *American Journal of Hematology*, *93*(8), 1091–1110. <https://doi.org/10.1002/ajh.25117>
- Rajkumar, S. V. (2020). Multiple myeloma: 2020 update on diagnosis, risk-stratification and management. *American Journal of Hematology*, *95*(5), 548–567. <https://doi.org/10.1002/ajh.25791>
- Röllig, C., Knop, S., & Bornhäuser, M. (2015). Multiple myeloma. *The Lancet*. [https://doi.org/10.1016/S0140-6736\(14\)60493-1](https://doi.org/10.1016/S0140-6736(14)60493-1)
- Ronchetti, D., Bogni, S., Finelli, P., Lombardi, L., Otsuki, T., Maiolo, A. T., & Neri, A. (2001). Characterization of the t(4;14)(p16.3;q32) in the KMS-18 multiple myeloma cell line. *Leukemia*, *15*(5), 864–865. <https://doi.org/10.1038/sj.leu.2402097>
- Saxe, D., Seo, E.-J., Bergeron, M. B., & Han, J.-Y. (2019). Recent advances in cytogenetic characterization of multiple myeloma. *International Journal of Laboratory Hematology*, *41*(1), 5–14. <https://doi.org/10.1111/ijlh.12882>
- Schauer, N. J., Liu, X., Magin, R. S., Doherty, L. M., Chan, W. C., Ficarro, S. B., Hu, W., Roberts, R. M., Iacob, R. E., Stolte, B., Giacomelli, A. O., Perera, S., McKay, K., Boswell, S. A., Weisberg, E. L., Ray, A., Chauhan, D., Dhe-Paganon, S., Anderson, K. C., ... Buhrlage, S. J. (2020). Selective USP7 inhibition elicits cancer cell killing through a p53-dependent mechanism. *Scientific Reports*, *10*(1), 5324. <https://doi.org/10.1038/s41598-020-62076-x>
- Sergentanis, T. N., Zagouri, F., Tsilimidos, G., Tsagianni, A., Tseliou, M., Dimopoulos, M. A., & Psaltopoulou, T. (2015). Risk Factors for Multiple Myeloma: A Systematic Review of Meta-Analyses. In *Clinical Lymphoma, Myeloma and Leukemia*. <https://doi.org/10.1016/j.clml.2015.06.003>
- Siegel, R. L., Miller, K. D., & Jemal, A. (2019). Cancer statistics, 2019. *CA: A Cancer Journal for Clinicians*. <https://doi.org/10.3322/caac.21551>
- Szalat, R., Samur, M. K., Fulciniti, M., Lopez, M., Nanjappa, P., Cleynen, A., Wen, K., Kumar, S., Perini, T., Calkins, A. S., Reznichenko, E., Chauhan, D., Tai, Y.-T., Shammas, M. A., Anderson, K. C., Femand, J.-P., Arnulf, B., Avet-Loiseau, H., Lazaro, J.-B., & Munshi, N. C. (2018). Nucleotide excision repair is a potential therapeutic target in multiple myeloma. *Leukemia*, *32*(1), 111–119. <https://doi.org/10.1038/leu.2017.182>
- Tavana, O., Sun, H., & Gu, W. (2018). Targeting HAUSP in both p53 wildtype and p53-mutant tumors. *Cell Cycle*, *17*(7), 823–828. <https://doi.org/10.1080/15384101.2018.1456293>
- Thorvaldsdóttir, H., Robinson, J. T., & Mesirov, J. P. (2013). Integrative Genomics Viewer (IGV): High-performance genomics data visualization and exploration. *Briefings in Bioinformatics*. <https://doi.org/10.1093/bib/bbs017>
- Tron, A. E., Belmonte, M. A., Adam, A., Aquila, B. M., Boise, L. H., Chiarparin, E., Cidado, J., Embrey, K. J., Gangl, E., Gibbons, F. D., Gregory, G. P., Hargreaves, D., Hendricks, J. A., Johannes, J. W., Johnstone, R. W., Kazmirski, S. L., Kettle, J. G., Lamb, M. L., Matulis, S. M., ... Hird, A. W. (2018). Discovery of Mcl-1-specific inhibitor AZD5991 and preclinical activity in multiple myeloma and acute myeloid leukemia. *Nature Communications*. <https://doi.org/10.1038/s41467-018-07551-w>
- Turnbull, A. P., Ioannidis, S., Krajewski, W. W., Pinto-Fernandez, A., Heride, C., Martin, A. C. L., Tonkin, L. M., Townsend, E. C., Buker, S. M., Lancia, D. R., Caravella, J. A., Toms, A. V., Charlton, T. M., Lahdenranta, J., Wilker, E., Follows, B. C., Evans, N. J., Stead, L., Alli, C., ... Komander, D.

- (2017). Molecular basis of USP7 inhibition by selective small-molecule inhibitors. *Nature*, 550(7677), 481–486. <https://doi.org/10.1038/nature24451>
- van Nieuwenhuijzen, N., Spaan, I., Raymakers, R., & Peperzak, V. (2018). From MGUS to multiple myeloma, a paradigm for clonal evolution of premalignant cells. In *Cancer Research*. <https://doi.org/10.1158/0008-5472.CAN-17-3115>
- Vikova, V., Jourdan, M., Robert, N., Requirand, G., Boireau, S., Bruyer, A., Vincent, L., Cartron, G., Klein, B., Elemento, O., Kassambara, A., & Moreaux, J. (2019). Comprehensive characterization of the mutational landscape in multiple myeloma cell lines reveals potential drivers and pathways associated with tumor progression and drug resistance. *Theranostics*, 9(2), 540–553. <https://doi.org/10.7150/thno.28374>
- Walker, B. A., Mavrommatis, K., Wardell, C. P., Cody Ashby, T., Bauer, M., Davies, F. E., Rosenthal, A., Wang, H., Qu, P., Hoering, A., Samur, M., Towfic, F., Ortiz, M., Flynt, E., Yu, Z., Yang, Z., Rozelle, D., Obenauer, J., Trotter, M., ... Morgan, G. J. (2018). Identification of novel mutational drivers reveals oncogene dependencies in multiple myeloma. *Blood*. <https://doi.org/10.1182/blood-2018-03-840132>
- Wang, Z., Kang, W., You, Y., Pang, J., Ren, H., Suo, Z., Liu, H., & Zheng, Y. (2019). USP7: Novel Drug Target in Cancer Therapy. *Frontiers in Pharmacology*, 10, 427. <https://doi.org/10.3389/fphar.2019.00427>
- Wuillème-Toumi, S., Robillard, N., Gomez, P., Moreau, P., Le Gouill, S., Avet-Loiseau, H., Harousseau, J. L., Amiot, M., & Bataille, R. (2005). Mcl-1 is overexpressed in multiple myeloma and associated with relapse and shorter survival. *Leukemia*. <https://doi.org/10.1038/sj.leu.2403784>
- Yang, Z., Huo, S., Shan, Y., Liu, H., Xu, Y., Yao, K., Li, X., & Zhang, X. (2012). STAT3 repressed USP7 expression is crucial for colon cancer development. *FEBS Letters*, 586(19), 3013–3017. <https://doi.org/10.1016/j.febslet.2012.06.025>
- Zhang, X. G., Gaillard, J. P., Robillard, N., Lu, Z. Y., Gu, Z. J., Jourdan, M., Boiron, J. M., Bataille, R., & Klein, B. (1994). Reproducible obtaining of human myeloma cell lines as a model for tumor stem cell study in human multiple myeloma. *Blood*, 83(12), 3654–3663.